Pharmacyclics, Inc. (NASDAQ:PCYC)

CAPS Rating: 1 out of 5

A pharmaceutical company focused on the development of products that improve existing therapeutic approaches to cancer and other diseases.

Recs

0
Player Avatar ormizd (75.90) Submitted: 7/10/2012 1:02:06 AM : Underperform Start Price: $59.14 PCYC Score: +23.77

It's part of the unsustainable run-up in biotechs.

Report this Post Reply

Featured Broker Partners


Advertisement